Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 13/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091570 | 0.88 | P2RX3 (0.45) | NPSR1KDM4EMAPK1ALDH1A1LMNA | |
| SCHEMBL3099441 | 0.81 | CYSLTR2 (0.51) | — | |
| SCHEMBL3090980 | 0.75 | LMNA (0.48) | KDM4EMAPK1ALDH1A1LMNAMAPT | |
| SCHEMBL3001949 | 0.73 | CCR2 (0.55) | — | |
| SCHEMBL22074018 | 0.73 | PPARG (0.43) | NPSR1MAPK1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL23916245 | 0.72 | KMT2A (0.37) | KDM4EMAPK1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL23270754 | 0.71 | TBXA2R (0.41) | NPSR1KDM4EMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL4384057 | 0.70 | CCR2 (0.58) | — | |
| SCHEMBL95661 | 0.70 | CYP4F2 (0.72) | KDM4EALDH1A1LMNAMAPTPOLB | |
| SCHEMBL23270735 | 0.70 | PTGES2 (0.46) | NPSR1KDM4EMAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933842-B1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | PANMIRA PHARMACEUTICALS LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-1933842-B1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | PANMIRA PHARMACEUTICALS LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| WO-2007047207-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | NPSR1 4409/4885KDM4E 2621/4885MAPK1 3571/4885 |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | NPSR1 4409/4885KDM4E 2621/4885MAPK1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.